
Quarterly report 2022-Q1
added 06-29-2022
Takeda Pharmaceutical Company Limited EBITDA 2011-2026 | TAK
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Takeda Pharmaceutical Company Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 509 B | 722 B | 358 B | 364 B | 313 B | 256 B | 47.1 B | 282 B | 324 B | 415 B | 474 B |
All numbers in JPY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 722 B | 47.1 B | 369 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Keros Therapeutics
KROS
|
69.1 M | $ 11.08 | -1.47 % | $ 412 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
-65 M | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 216.97 | -0.5 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 19.25 | 0.1 % | $ 900 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-16.2 M | $ 0.67 | 10.54 % | $ 7.67 M | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.4 | -0.36 % | $ 357 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
-127 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.63 | - | $ 16.5 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
12.6 M | $ 199.63 | -0.36 % | $ 3.65 B | ||
|
Longeveron
LGVN
|
-22.5 M | $ 0.9 | -5.5 % | $ 15.8 B | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 4.3 | -2.83 % | $ 824 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
-5.09 M | $ 2.65 | -0.38 % | $ 5.08 M | ||
|
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | ||
|
Harmony Biosciences Holdings
HRMY
|
232 M | $ 27.05 | -1.99 % | $ 1.56 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M |